Natdac

Natdac is the generic version of dakinza (daclatasvir)
on 17th december 2105 natco pharma got approval for generic daclatasvir dihydrochloride (“daclatasvir”) tablets, natdac 30mg & natdac 60mg, from drugs controller general (india).
Daclatasvir (natdac) is the first-in-class ns5a inhibitor used in combination with sofosbuvir for the treatment of patients with chronic hepatitis c virus (hcv) genotype 3 infection. Compared to other treatment options, this combination not only increases the cure rate, but is also regarded as a valuable treatment option in some of the difficult-to-treat hcv patient subsets.